Treating Neurodegenerative Disorders Linked to TDP-43 Pathology
Treating Neurodegenerative Disorders Linked to TDP-43 Pathology
Embedded Files
SLU ID 22-001 | RNA-based approach to decrease TDP-43 pathology
SLU ID 22-001 | RNA-based approach to decrease TDP-43 pathology
Intellectual Property Status
Intellectual Property Status
Seeking
Seeking
Provisional patent application filed
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
Background
Background
TDP-43 protein aggregation and loss of function are hallmarks of Amyotrophic Lateral Sclerosis (ALS), frontotemporal dementia, limbic-predominant age-related encephalopathy, Alzheimer's disease, multisystem proteinopathy, and chronic traumatic encephalopathy. Currently, there are no treatments for neurodegenerative disorders linked to TDP-43 pathology.
Overview
Overview
Researchers at Saint Louis University have designed and investigated specific molecules to decrease TDP-43 aggregation and recover protein function.
Benefits
Benefits
The potential benefits of this technology include:
increasing the number of potential treatments for various neurodegenerative disorders linked to TDP-43 pathology.
Applications
Applications
Potential applications of this technology include developing treatments for:
Amyotrophic Lateral Sclerosis (ALS)
frontotemporal dementia
limbic-predominant age-related encephalopathy
Alzheimer's disease
multisystem proteinopathy
chronic traumatic encephalopathy
Opportunity
Opportunity
Saint Louis University is seeking a partner to further develop and commercialize this technology.
Report abuse